TRVI · Trevi Therapeutics, Inc. · Executive Compensation
$13.49
-0.23 (-1.68%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.96B
Shares
142.56M
Volume · Nov 20
1.37M
Avg daily vol (3M)
1.97M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $3,944,892 |
| James Cassella | Chief Development Officer | $1,637,220 |
| Farrell Simon | Pharm. D. Chief Commercial Officer | $1,355,897 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $2,589,035 |
| James Cassella | Chief Development Officer | $1,441,119 |
| Lisa Delfini | Chief Financial Officer | $1,187,403 |
| Farrell Simon | Pharm. D. Chief Commercial Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $1,687,298 |
| Thomas Sciascia | Chief Scientific Officer | $977,125 |
| David Clark | M.D., MBChB Chief Medical Officer | $610,638 |
| James Cassella | Chief Development Officer | — |
| Lisa Delfini | Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $898,095 |
| David Clark | M.D., MBChB Chief Medical Officer | $580,781 |
| Thomas Sciascia | Chief Scientific Officer | $577,295 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $1,527,439 |
| William Forbes | Pharm. D. Chief Development Officer | $1,180,794 |
| Thomas Sciascia | Chief Scientific Officer | $717,544 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $1,441,457 |
| Yann Mazabraud | Former Chief Commercial Officer and Head of International | $716,856 |
| Chris Seiter | Former Chief Financial Officer | $716,218 |
| Thomas Sciascia | Chief Medical Officer | $709,894 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $2,810,719 |
| Yann Mazabraud | Former Chief Commercial Officer and Head of International | $914,666 |
| Thomas Sciascia | Chief Medical Officer | $786,845 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Yann Mazabraud | Chief Commercial Officer and Head of International | $1,012,833 |
| Jennifer Good | President and Chief Executive Officer | $528,250 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David Hastings | Chief Financial Officer and principal financial officer | Appointed | 2025-12-05 |
|
Lisa Delfini
“The Company appreciates the service of Ms. Delfini and her resignation is not the result of any disagreement with the Company on any matter, including the Company’s operations, policies or practices.”
|
Chief Financial Officer | Resigned | 2025-08-20 |
| James Cassella | member of the Board of Directors | Resigned | 2024-10-01 |
| James Cassella | Chief Development Officer | Appointed | 2024-10-01 |
Leadership
- Christopher Galletta Chief Accounting Officer
- Anne VanLent Board Member
- Dominick C. Colangelo Board Member
- James V. Cassella Board Member
- Jennifer Good Board Member
Key facts
CIK
1563880
CUSIP
89532M101
13F (30d)
230 filings
216 filers
Visit website
Investor relations